Courtagen Life Sciences, Inc. Releases Most Comprehensive Rapid DNA Test Targeting Mito Exome

WOBURN, Mass.--(BUSINESS WIRE)--Courtagen Life Sciences, Inc., a privately held life sciences company that provides innovative proteomic and genomic products and services to the life sciences industry, today announced the expansion of their genetic test menu. The new genetic test, nucSEEKPDx™, will sequence approximately 1,100 nuclear genes constituting the mitochondrial exome, which encodes the vast majority of proteins found in the mitochondrion. This test is by far the most comprehensive test on the market for the management of mitochondrial disorders. Targeting the complete mito exome provides a greater potential to identify rare variants predicted to disrupt normal mitochondrial function, allowing for an exact diagnosis in a large proportion of patients that remain undiagnosed by other methods. Over 95% of the target bases are sequenced to an average coverage of 400x, providing highly accurate and sensitive results.